These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 17726033)

  • 1. COX-2 inhibitor.
    Gøtzsche PC; Bjarnason NH
    Rheumatology (Oxford); 2007 Oct; 46(10):1623-4; author reply 1624-5. PubMed ID: 17726033
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
    Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo.
    Bingham CO; Smugar SS; Wang H; Tershakovec AM
    Rheumatology (Oxford); 2009 Sep; 48(9):1122-7. PubMed ID: 19589894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical inquiries. Do COX-2 inhibitors worsen renal function?
    Wall R; Strickland C; Jamieson B; Lo V
    J Fam Pract; 2007 Nov; 56(11):957-8. PubMed ID: 17976347
    [No Abstract]   [Full Text] [Related]  

  • 5. Use and misuse of the p-value.
    Lesaffre E
    Bull NYU Hosp Jt Dis; 2008; 66(2):146-9. PubMed ID: 18537787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The efficacy of selective Cox-2-inhibitors in comparison with conventional NSAIDs].
    Krüger K
    MMW Fortschr Med; 2005 Aug; 147(31-32):28-30. PubMed ID: 16128193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed drug eruption due to etoricoxib in a patient with tolerance to celecoxib: the value of patch testing.
    Gómez de la Fuente E; Pampín Franco A; Caro Gutiérrez D; López Estebaranz JL
    Actas Dermosifiliogr; 2014 Apr; 105(3):314-5. PubMed ID: 24661957
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.
    Sakamoto C; Soen S
    Digestion; 2011; 83(1-2):108-23. PubMed ID: 21042022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of rofecoxib 12.5 mg and celecoxib 200 mg in two similarly designed osteoarthritis studies.
    Birbara C; Ruoff G; Sheldon E; Valenzuela C; Rodgers A; Petruschke RA; Chang DJ; Tershakovec AM
    Curr Med Res Opin; 2006 Jan; 22(1):199-210. PubMed ID: 16393445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib.
    Hinz B; Dormann H; Brune K
    Arthritis Rheum; 2006 Jan; 54(1):282-91. PubMed ID: 16385545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What's all the fuss? Safety concerns about COX-2 inhibitors rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wooltorton E
    CMAJ; 2002 Jun; 166(13):1692-3. PubMed ID: 12126328
    [No Abstract]   [Full Text] [Related]  

  • 12. Is the demonstration of adenoma reduction with rofecoxib a pyrrhic victory?
    Lynch PM
    Gastroenterology; 2006 Dec; 131(6):2003-5. PubMed ID: 17188962
    [No Abstract]   [Full Text] [Related]  

  • 13. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
    Rahme E; Hunsche E; Toubouti Y; Chabot I
    Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
    Hsiao FY; Tsai YW; Huang WF
    Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The COX-2 inhibitors--an update.
    Furberg CD
    Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
    [No Abstract]   [Full Text] [Related]  

  • 16. [3 questions about gastrointestinal risk. Are coxibs here clearly better than NSAID?]].
    Krüger K
    MMW Fortschr Med; 2006 Nov; 148(48):12. PubMed ID: 17615761
    [No Abstract]   [Full Text] [Related]  

  • 17. Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib.
    Ponce V; Muñoz-Bellido F; Moreno E; Laffond E; González A; Dávila I
    Contact Dermatitis; 2012 Feb; 66(2):107-8. PubMed ID: 22233472
    [No Abstract]   [Full Text] [Related]  

  • 18. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
    Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG
    J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis.
    Zweers MC; de Boer TN; van Roon J; Bijlsma JW; Lafeber FP; Mastbergen SC
    Arthritis Res Ther; 2011; 13(5):239. PubMed ID: 21955617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2 inhibitor, celecoxib, may prevent lung cancer.
    Oncology (Williston Park); 2011 Aug; 25(9):848-9. PubMed ID: 21936449
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.